MIRROR results showed 12-month safety/efficacy support MTX co-therapy w/ pegloticase. No IRs after 6mo of tx and increased resolution of tophi at wk 52. I use MTX in my gout pts on Pegloticase. Are you #rheumtwitter? Abs 0001 #ACR22 @RheumNow https://t.co/FLwOmAYrS4

• 12-month Findings of the Randomized, Double-Blind, Placebo-Controlled, Multicen…

Role of acquired mutations in #gout Risk factor for gout CHIP? Individuals with CHIP are more likely to developed acute episodes of gouty episodes More IL-1B in cells with somatic mutations like CHIP @rheumnow #ACR22 #yearinreview https://t.co/k3VeZuTCln

CHIP- need to know! Somatic mutations fondly known as CHIP - not the salty ones. Clonal hematopoeisis of uncertain significance. Older Pts getting somatic mutations account for more CVS, malignancies , one change in TET2 increased gout #ACR2022 @RheumNow John Barga Yr in Review https://t.co/6bnqnkDFpL

MTX increases pegloticase efficacy in MIRROR trial. Similar safety too. Shame the cost of pegloticase is prohibitive in Australia... @RheumNow #ACR22 #yearinreview

Year in Review #ACR22 Pegloticase and MTX now FDA approved co-administration for tophaceous gout to prevent anti-drug antibodies ⁦@RheumNow⁩ https://t.co/EPtOrjJqLd

Preview of what is sure to be discussed more in detail later.. MIRROR trial of MTX co-administration with pegloticase in treatment of gout. MTX co-administration improved control of gout, reduced infusion reactions @RheumNow #ACR22 https://t.co/r0MEq1rkgO